Genmab announced the termination of clinical development for acasunlimab, a bispecific antibody previously advanced with BioNTech, citing strategic reprioritization after the partner withdrew. The decision halts a Phase 3‑intended pathway and frees resources for other pipeline assets. Bispecifics remain a high‑value but technically risky modality; this program’s discontinuation illustrates the portfolio churn that can follow partner realignments and negative risk‑reward assessments. Genmab will need to communicate next steps to investors and may reallocate capital toward higher‑conviction programs or in‑licensing opportunities.